Genmab A/S (OTCMKTS:GNMSF – Get Free Report) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 106,477 shares, a decline of 44.4% from the September 15th total of 191,429 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 359 shares, the short-interest ratio is presently 296.6 days.
Genmab A/S Price Performance
GNMSF stock remained flat at $367.00 during trading on Friday. The firm has a market cap of $22.60 billion, a price-to-earnings ratio of 28.78 and a beta of 0.75. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. Genmab A/S has a 1 year low of $232.34 and a 1 year high of $396.97. The firm has a 50 day moving average price of $341.21 and a 200-day moving average price of $293.92.
About Genmab A/S
Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.
Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies.
Recommended Stories
- Five stocks we like better than Genmab A/S
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
- Palantir’s Potential Next Catalyst After Retail Profit-Taking
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
